A panel of novel recombinant single-chain variable fragment (scFv) antibody against human immunodeficiency virus type-1 (HIV-1) was isolated and characterized. We generated human scFvs using RNA harvested from cervical B lymphocytes of Kenyan prostitutes who are highly exposed to HIV-1, but remain persistently seronegative. The variable regions of the heavy (VH) and light (VL) chain antibody genes were selected as hybrids using guided-selection with the VL and VH, respectively, of a derivative of IgGb 12 using the phagemid vector pComb3X. 
INTRODUCTION H
UMAN IMMUNODEFICIENCY VIRUS TYPE-1 (HIV-1) has become the modern plague of mankind. The design of vaccines capable of preventing the transmission of HIV-1 requires a deeper understanding of what is needed for an effective host defense from retroviral invasion of the human immune system. Of particular relevance, a group of epidemiologically resistant Kenyan commercial sex workers have been shown to resist HIV-1 infection despite frequent exposure. (1) These subjects characteristically have HIV-1 specific cell-mediated immunity [2] [3] [4] and HIV-1 specific mucosal IgA (5) without detectable serum IgG reactive with HIV-1. Other exposed seronegative prostitutes (6) and discordant partners of HIV-1 infected individuals (7) also possess HIV-1 reactive IgA in the absence of detectable serum IgG, respectively. Recently, purified plasma and mucosal IgA from Kenyan HEPS were shown to be neutralizing to a primary HIV-1 isolate in vitro (8) and to inhibit transcytosis of HIV-1 in an epithelial cell model. (9) Thus, mucosal antibodies may contribute to the apparent broad HIV-1 resistance found in HEPS individuals.
Antibodies have played a useful role in defining virus-host interactions and in revealing the antigenic structure of viruses. As antibodies are the only host defense capable of completely preventing an infection, (10) the prophylactic induction of locally protective antibodies should therefore be an attractive goal for HIV vaccines. Neutralizing monoclonal antibodies (MAbs) to HIV-1 also have potential therapeutic value for the prevention of infection after accidental exposures to the virus, and for the interruption of maternal-fetal transmission of HIV-1. Moreover, these antibodies can be used to identify potential protective B-cell epitopes to facilitate vaccine design. The viral neutralization sites for HIV-1 reside largely in the envelope protein. (11) The Envelope protein, which consists of gp120 and gp41, has been shown to contain a variety of epitopes capable of eliciting neutralizing antiviral antibody.
Mucosal antibody has been postulated to play an important role in the acquisition of resistance to progressive HIV-1 infection. A likely explanation is that these IgA responses are acquired through sexual exposure to HIV-1, and because lymphocytes tend to traffic to sites of initial antigen encounter the local cervical lymphocyte pool of HEPS should be enriched with B cells producing antibody to HIV-1. (12) The demonstration of neutralizing IgA in cervical secretions, and the predominance of B cells in the local cervical mononuclear cell population, (13) would therefore make the cervical B-cell pool a potentially valuable source of antibodies.
Of the human MAbs to HIV-1 that have been reported, the IgG MAb b12 is among the most potent in virus neutralization activity. (14, 15) IgGb12 was selected from a combinatorial antibody library derived from a long-term asymptomatic HIV-1 seropositive patient, and the activities of b12 variants were subsequently improved with alternating rounds of in vitro mutagenesis and selection. IgGb12 recognizes a highly conserved but relatively obscure epitope on gp120 shared by diverse isolates, and this antibody can neutralize primary HIV-1 isolates in vitro. (16) Passive transfer of IgGb12 into hu-PBL-SCID mice conveys protection from challenge with primary isolates of HIV-1, (17) and protect macaques from vaginal challenge with R5 isolates. (15) Based on these findings, we speculate that it may be feasible to develop a vaccine capable of inducing antibodies with potency akin to IgGb12, that may act as a preformed protective mucosal immune barrier. To attain this goal, the immunogenicity and immunodominance of protective epitopes on the HIV-1 envelope proteins on the mucosal surface must be investigated.
Herein, we describe the isolation and characterization of a panel of novel recombinant single-chain variable fragment (scFv) antibody against HIV-1. The genes encoding these antibody binding domains were cloned from total RNA of cervical mononuclear cells, collected by routine noninvasive gynecological procedures. Thereby, we tested the feasibility of selecting new recombinant MAbs from limited numbers (1000-100,000 per sample) of lymphocytes. The libraries of cloned cervical VH or VL genes were paired with the VL or VH genes for a previously described variant of the human IgG anti-gp120 MAb, b12, respectively. Novel antibodies specific for gp120 were isolated from these hybrid libraries using a specially tailored phage-selection. (18) In these studies, the guided selection strategy was designed for the section of hybrid MAbs with broad reactivity for diverse HIV-1 envelope proteins now found in low frequency in East-African isolates. Because cervical antibodies may contribute to protection against HIV-1 infection, the ability to study cervical B-cell pools will help to identify candidate vaccine antigens that may be important for the development of mucosal vaccines.
MATERIALS AND METHODS

Study subjects, cervical lymphocyte collection, and RNA purification
Samples were collected from female commercial sex workers in the Pumwani area of Nairobi, Kenya, as described previously. (5) To collect mucosal lymphocyte samples, cytobrushes were used during regular scheduled clinic visits. Immediate after collection, the cytobrush was placed into RNA lysis buffer containing guanidium isothiocyanate (TRIreagent, Molecular Research Diagnostics, Inc., Cincinnati, OH), and the RNA was later purified using the Eppendorf 5-Prime phaselock gel tubes, a procedure ideal for the isolation of small amounts of total RNA from samples containing extraneous material. Each cytobrush sample contains between 1000-100,000 lymphocytes (R. Kaul, personal observations 
Reverse transcriptase (RT)-PCR and Phagemid System
First strand cDNA was reverse transcribed from total RNA using oligo-dt (15) primers and the Thermoscript cDNA kit (GIBCO-BRL, Fredrich, MI). Due to the limited amount of cDNA retrieved from each sample, the previously described oligonucleotide primers were pooled for the separate PCR amplification of human IgA heavy chain genes or light (kappa and lambda) chain genes, respectively (Table 1) . Two additional primers were also used, that included the kappa forward primer, HSCK4I-F (5Ј-TGG CCC AGG CGG CCG GCG CGC CTG AAC TCA CGC AGT CTC CAG GC-3Ј), and the VH primer, HSCVH31-FL (5Ј-GGT GGT TCC TCT AGA TCT TCC TCC TCT GGT GGC GGT GGC TCG GGC GGT GGT GGG GAG CAG CTC GAG CAG TCT GGG GCT GAG GTG-3Ј). In one reaction, genes were amplified with the heavy chain (IgA1/A2) back primer HSCA-B (5Ј-CCT GGC CGG CCT GGC CAC TAG TGA CCT TGG GGC TGG TCG GGG ATG C-3Ј). In contrast, attempts to amplify rearranged IgG heavy chain Vgenes from cervical cDNAs were unsuccessful, which supports IgA as being a predominant locally expressed heavy chain class in the cervix.
To generate composite genes for scFv antibodies, overlap PCR was performed as described with human IgA1/2 and kappa and lambda primer long-linker scFv sets (19, 20) with the primers HSC-F (5Ј-GAG GAG GAG GAG GAG GAG GCG GGG CCC AGG CGG CCG AGC TC-3Ј) and RSC-B (5Ј-GAG GAG GAG GAG GAG GAG CCT GGC CGG CCT GGC CAC TAG TG-3Ј). Thereby, a scFv antibody library from ML556 was made with VL genes fused via a synthetic linker to VH genes, which were linked to the gene-encoding the C-terminal domain of the Heavy Chain forward HSCVH1-FL 5Ј-GGT GGT TCC TCT AGA TCT TCC TCC TCT GGT GGC GGT GGC TCG GGC GGT GGT GGG CAG GTG CAG CTG GTG CAG TCT GG-3Ј HSCVH2-FL 5Ј-GGT GGT TCC TCT AGA TCT TCC TCC TCT GGT GGC GGT GGC TCG GGC GGT GGT GGG CAG ATC ACC TTG AAG GAG TCT GG-3Ј HSCVH35-FL 5Ј-GGT GGT TCC TCT AGA TCT TCC TCC TCT GGT GGC GGT GGC TCG GGC GGT GGT GGG GAG GTG CAG CTG GTG SAG TCT GG-3Ј HSCVH3a-FL 5Ј-GGT GGT TCC TCT AGA TCT TCC TCC TCT GGT GGC GGT GGC TCG GGC GGT GGT GGG GAG GTG CAG CTG KTG GAG TCT G-3Ј HSCVH4-FL 5Ј-GGT GGT TCC TCT AGA TCT TCC TCC TCT GGT GGC GGT GGC TCG GGC GGT GGT GGG CAG GTG CAG CTG CAG GAG TCG GG-3Ј HSCVH4a-FL 5Ј-GGT GGT TCC TCT AGA TCT TCC TCC TCT GGT GGC GGT GGC TCG GGC GGT GGT GGG CAG GTG CAG CTA CAG CAG TGG GG-3Ј HSCVH31-FL 5Ј-GGT GGT TCC TCT AGA TCT TCC TCC TCT GGT GGC GGT GGC TCG GGC GGT GGT GGG GAG CAG CTC GAG CAG TCT GGG GCT GAG GTG-3Ј
IgA 3Ј anti-sense, back primer*
HSCA-B 5Ј-CCT GGC CGG CCT GGC CAC TAG TGA CCT TGG GGC TGG TCG GGG ATG C-3Ј Overlap Extension Primers CSC-F (sense) 5Ј-GAG GAG GAG GAG GAG GAG GCG GGG CCC AGG CGG CCG AGC TC-3Ј
RSC-B (anti-sense) 5Ј-GAG GAG GAG GAG GAG GAG CCT GGC CGG CCT GGC CAC TAG TG-3Ј *The Sfi I site is underlined; B
filamentous phage protein pIII, enabling display on the surface of filamentous phage following VCS M13 helper phage rescue, as described. (19) The Kenyan VH IgA repertoire from the cervical lymphocytes of 12 HEPS subjects were cloned into the pComb3X phagemid vector, also as described. (19) The result of this approach is the display of a IgA/kappa/lambda polypeptides representing the product of scFv cDNA ligated in frame with the C-terminus of pIII via directional Sfi I sites within the pComb3X phagemid vector. (20) Phagemid selection and scFv characterization
The H31/4L MAb is an affinity improved IgGb12 with several point mutations in the VH region and the parental light chain of IgGb12, 4L. H31/4L neutralizes many TCLA and PI strains of HIV-1. Briefly, via overlap-PCR with linker oligonucleotides, the cDNA of VH and VL of the b12 mutant H31/4L Fab were PCR amplified and linked to cDNAderived cervical VL and VH genes, respectively. For the IgA VH library, the repertoires in PCR-amplified cervical B lymphocyte cDNA from 12 HEPS subjects was pooled, and then fused to the 4L VI cDNA, prior to cloning into the pComb3X phagemid vector. Similarly, the HEPS cervical V kappa and V lambda cDNA repertoire was PCR-amplified and fused to the H31 VH cDNA and then cloned into pComb3X. A single round of affinity selection was performed with 15 wash steps in the presence of 5 g/mL of native IgGb12 as a competitor, on wells coated with gp120 IIIB protein, generously provided by Dr. Pat Earl (National Institutes of Health, Bethesda, MD). The gp120 binding phagemids were eluted and expanded, as described, (19) and then used to infect F pilus ϩ XL-1 E. coli (Stratagene, Cambridge, UK), and then plated onto LB/carbenecillin (100 g/mL) plates. To assess the binding characteristics of the scFvs, bacterial supernatants from individual clones transformed into Top-10 E. coli (amber nonsuppressor-strain) were expressed without the pIII fusion protein and screened for binding to gp120 SF2 in standard EIA. To enable detection in both enzyme immunoassay (EIA) and flow cytometric assays was via an engineered epitope tag in the pComb3X vector an hemagglutin (HA) is fused to the carboxy-end of the scFv molecules upstream of the amber stop codon. Binding was detected with a high affinity rat anti-HA tag antibody (Roche, Nutley, NJ), followed by a goat anti-rat fluorescein isothiocyanate (FITC) or horseradish peroxidase (HRP) conjugated commercial antibody (Roche).
The recombinant and wildtype vaccinia strains were generously provided by Dr. Christopher Brodeur (Uniformed Services University, Bethesda, MD). Log phase 293T cells were infected at an multiplicity of infection (MOI) of 2 with recombinant vaccinia expressing Ugandan (A) HIV-1 envelopes. Cells were harvested at 24 h by mechanical scraping, blocked in FACS buffer [1% bovine serum albumin (BSA), 25 mM HEPES, phosphate-buffered saline (PBS) pH 7.2] and stained with antibodies at room temperature. Cells were then treated with 2% paraformaldehyde to destroy any residual infectious vaccinia virus. Data was acquired for stained cells with a FACScan (Becton-Dickinson, Oxnard, CA). The in vitro p24 neutralization assay was performed, as described. (16) 
RESULTS
Characteristics of the cloned human cervical immunoglobulin repertoire
To assess the diversity of antibody genes cloned into the phagemid vector from cervical lymphocytes, Alu I restriction enzyme digestion was performed on individual phagemid clones from the unselected combinatorial IgA library. This demonstrated diverse restriction fragments patterns indicating that the library consisted of diverse variable region genes from the mucosal lymphocytes (data not shown). To further characterize these plasmids, individual clones were then randomly selected for detailed sequence analysis using vector-specific primers. The sequences show that diverse Ig V-genes regions can be cloned from small samples of cervical lymphocytes. Light chains of both kappa (Vk-1, and 3) and lambda (VLambda 1, 2, and 3) isotypes were identified among clones of the unselected mucosal library. Heavy chain IgA variable region genes have highest identity with germline members of the VH1, 3, 4, and 5 VH gene families. Examination of several random, unselected cloned cervical V-genes shows each is found only once in this library, indicating that our primer sets amplify a representative assortment of heavy and light chain variable region gene cDNAs from cervical B cells (Fig. 1) .
Selection of gp120 specific hybrid MAbs
Initial selection experiments were done with a ScFv phagemid library produced from the cervical lymphocytes of individual ML556. This library was biopanned for three rounds upon a recombinant gp41 (Intracel, Cambridge, MA) and several Chlamydia trachomatis antigens. In all cases the ML556 library failed to show any specific enrichment, and individual clones were nonbinding. We could not conclude that our library was functional because there is no precedent for small cervical antibody libraries based upon this failure. Furthermore, in retrospect, our failure to select gp41 specific MAbs from the scFv library made from ML556 cervical lymphocyte cDNA could have been predicted as ML556 is one of those rare resistant prostitutes without measurable mucosal antibody to gp160 in her secretions (R. Kaul, observations). Thus, we adopted the guided selection strategy to test the feasibility of using cervical B cell RNA. Cervical VH and VL cDNA was recombined with MAb H31-VH and 4L-VL to produce functional libraries. Based upon cell counting experiments with other cytobrush samples we estimate that the chain shuffled libraries from 12 individuals would have a maximum cellular diversity of less than approximately 12 ϫ 100,000 total lymphocytes. We rationalize that the use of the functional H31/4L binding domains, which were optimized through prokaryotic expression and selection, would facilitates maximum sampling of the cervical antibody domains as hybrids and the b12 domains are highly expressed in E. coli. This could help to reduce any potential deleterious effects of random pairings formed during the randomized VH and VL pairing inherent in this cloning procedure. (21) The use of the b12 variant was intentional as we hoped to at least select new hybrid scFv with diversified gp120 binding reactivity should the guided selection succeed. The cervi-cal light chain shuffled library contained 3.3 ϫ 10 7 hybrid clones comprised of kappa and lambda isotypes with the H31 heavy chain. The cervical IgA heavy chain shuffled library contained 6.4 ϫ 10 7 hybrid clones with the 4L light chain. Using gp 120 IIIB in solid phase, we selected phage-borne scFv from both libraries.
Four novel binding clones were identified using enzymelinked immunosorbant assay (ELISA) (Fig. 2a) . The hybrid clones had comparable gp120 binding reactivity to the parental H31/4L when expressed as scFv in bacterial supernatant. We sequenced the VH and VL of these binding clones to confirm the selection of new V-gene binders. Two cervical VH domains (IgA6 and IgA9) were identified in combination with the parental 4L and were expressed well in vitro. Two cervical VL, clone 5-kappa and 30-lambda domains (signifying the light chain isotype classes) were identified in scFv paired with the parental H31 VH-gene. The molecular sequences of the cervical VH and VL domains selected in hybrid ScFv were determined and are shown in Figs. 3 and 4 , respectively. Characterization of the variable region genes of the binding clones revealed that they were encoded by diverse antibody variable region genes and without evidence of clonal restriction. Of note, the IgA6-VH was selected independently in several different phagemid clones suggesting it was enriched in the eluted phagemid population. Because of the general importance of the VH in determining antigen specificity, (22) the hybrid scFv molecules with new VH domains were further tested for binding to the gp120 oligomer expressed on the surface of eukaryotic cells. These hybrid molecules bind to cell-expressed HIV-1 envelope of a Ugandan clade A strain in flow cytometry compared to a control antibody (Fig. 2b) . IgA6/4L in particular is capable of good binding to the clade A gp120 molecule, with 2 decades of binding, suggesting a new epitope is targeted on the envelope molecule. Hybrid scFv were further assessed in in vitro HIV virus neutralization assay. Purified hybrid scFv from clone IgA6/4L neutralizes HXB2, in contrast to clone IgA9/4L, which did not produce significant neutralization relative to control antibodies (Fig.   BERRY ET AL.  102   FIG. 2 . Identification of the selected hybrid ScFvs. (A) Clade B gp120SF2 was used to coat wells of a 96 well plate. Single colony bacterial supernatants were tested in ELISA to identify binding clones for further analysis. Muck 4 is a previously selected single chain which binds to an irrelevant antigen. IgA6/4L, and IgA9/4L were selected from the cervical heavy chain shuffled library and have novel VH genes; H31/5kappa, and H31/30lambda were selected from the cervical light chain shuffled library and have novel light chain variable regions. The parental H31/4L was similarly expressed for a positive control. (B) Demonstration of binding of purified hybrid ScFv on the gp120 oligomer expressed on cells in flow cytometry. Human 293T cells were infected with recombinant vaccinia virus constructs expressing the gp160 molecule. Clone muck 4 is a ScFv to an irrelevant antigen and used to control specificity of binding (green fill). The parental H31/4L (green line) binds to an epitope in the CD4 binding site which is present on both the clade A and B gp120 molecules. IgA9/4L [blue line] binds with a similar shift as the H31/4L. IgA6/4L binds with two decade of shift to both gp120 molecules suggesting it binds to a conserved epitope present on these diverse gp120 molecules (red line). (C) In vitro neutralization of HIV-1 with monoclonal antibodies. Serial dilution's of the mAbs were incubated with the HXB2 virus for 30 minutes at 370c before being transferred to PBLs. Viral growth was estimated using standard P24 ELISA on the supernatant following 7 days growth . The OD is proportional to the relative amount of p24 produced at 7 days in human PBL culture. The assays were performed in triplicate and in a blinded fashion. The whole IgG B12 and ScFvs H31/4L, and Muck 4 were used as controls. ᭜ IgGb12; ᭡ H31/41 scfv; ᭺ muck 4; ٗ IgA6/4L; and ଝ IgA9/4L. 2c). The H31/4L ScFv neutralizes this T-cell line adapted (TCLA) isolate very well, which is consistent with the improved affinity of H31/4L for this envelope compared with the original b12 antibody. These data show that a hybrid cervical scFv MAb IgA6/4L neutralizes HXB2 in vitro, and displays unique reactivity for an envelope epitope common to isolates from clades A and B.
Characterization of the combined cervical MAbs
The cervical antibody binding domains were tested for gp120 binding activity when cervical VH cDNA is recombined with cervical VI cDNA (Fig. 5a ). The gp120 binding ability was retained by IgA6-VH linked to either of the two selected cervical VL domains. Both the IgA6/2k and the IgA6/30 combinations show significant binding to the clade B gp120. The binding curve for IgA6/5k and the IgA6/30I cervical ScFvs were tested with purified scFv protein in a capture EIA assay on a clade B gp120 JRFL . While there was no detectable binding by the IgA9 heavy chain when recombined with either of the light chains and expressed as supernatant, we have yet normalized the expression of the IgA9 clones as there may be inclusion formation or toxicity from these proteins. Neither IgA6/5k nor IgA6/30I are inhibited by whole
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FIG. 3.
Nucleotide sequences of the selected heavy-chain variable regions. The sequences were compared to the known immunoglobulin sequences in the databanks on the worldwide web. The nucleotide and inferred amino acid translations of IgA6 VH (upper) and IgA 9 VH (lower) and depicted in alignment with the closest matching germline alleles for human VH, DH, and JH. A DH germline match for IgA9 was not identified by the ImmunoGenetics program. The nucleotide sequences for IgA6 and IgA9 have been submitted to GenBank (accession numbers AY044149 and AY044150, respectively). Alignments and CDR delineation were performed according to LeFranc et al. (8) and the ImmunoGenetics databanks. "Ϫ" denotes identity, and ‫"ء"‬ denotes a deletion.
IgGb12 antibody for gp120 binding over several logs b12 protein concentration (Fig. 5b) . This shows that the gp120 epitope targeted by the cervical MAbs are different from the parental IgGb12 epitope. This is consistent with a previously identified hepatitis MAb, where changing the light-chain partner was found to alter epitope specificity. (23) 
DISCUSSION
We used phage display to select human gp120 binding domains from cervical B-lymphocytes of HEPS. Using gp120 in solid phase we selected hybrid phage-borne ScFv from a chain shuffled IgA/k/ library generated from the pooled cervical B lymphocytes of 12 Kenyan HEPS. The HEPS cervical B cells contain antibody binding domains, which neutralize HIV-1. This is corroborates previous findings of IgA antibody to HIV-1 in HEPS, (5) and the neutralizing capacity of these secreted antibodies in two different in vitro culture assays. (8, 9) The neutralization of HIV-1 by hybrid clone IgA6/4L correlates with the ability to bind to the gp120 envelope oligomer on cells (Fig.  2b) . Consistent with the compartmentalized nature of the IgA response to HIV, local B cells on the cervix directly produce antibodies to HIV-1. Further tests on the neutralizing spectrum BERRY ET AL. 104
FIG. 4.
Nucleotide sequences of the selected light-chain variable regions. The sequences were compared to the known immunoglobulin sequences in the databanks on the worldwide web. The nucleotide and inferred amino acid translations of the 30-lambda VL (upper) and 5-kappa VL (lower) and depicted in alignment with the closest matching germline alleles for human VL, and JL. The 30-lambda VL has a polymorphism in the CDR1 domain with a deletion of codon 35. The nucleotide sequences for 30-lambda and 5-kappa VLs have been submitted to GenBank (accession numbers AY044151 and AY044152, respectively). Alignments and CDR delineation were performed according to LeFranc et al. (8) and the ImmunoGenetics databanks. Ϫ denotes identity; and ‫ء‬ denotes a deletion. Commercial polyclonal sheep anti gp120 C-terminus IgG (International Enzymes Inc.) was used to capture recombinant gp120JRFL on a 96-well polystyrene plate. Purified ScFv were serially diluted in 2% BSA-PBS and reacted upon a 4% BSA preblocked plate. Commercial secondary antibody (anti-HA tag-HRP; Roche) was used to detect the ScFv molecules. B-(INSET). Whole recombinant IgG B12 molecular was tested in competition against cervical MAbs IgA6/301 (filled circles) or IgA6/5k (filled triangles) for binding to gp120JRFL. The concentration of the ScFvs were normalized at 7.5 g/mL in 2% BSA, which was about 50% of maximum signal. The open symbols represent binding without IgG B12 as an inhibitor; the diamond is an irrelevant ScFv control. The whole IgG B12 molecule showed no inhibition of binding to either ScFv over several logs, which is consistent with the use of whole IgG B12 as an inhibitor during the wash steps in the phage selection. of these new cervical V-domains on additional TCLA and primary isolates are underway. The reason for the absence of in vitro neutralization seen with MAb IgA9/4L is not clear, but could be due to unknown parameters for neutralization of HIV-1 in vivo on the mucosal surface. Nevertheless, the IgA9/4L acts as an additional in vitro control for neutralization by new VH with the parental 4L light chain. This study shows that MAbs can be selected from cDNA cloned from the ectocervical plasmablast population of HEPS. This is the first set of recombinant MAbs to be derived from B cells of the human cervix. While the human cervix is rich in B cells and plasmablasts, (13) the clonal diversity was uncharacterized. Johansson et al. (24) showed that CD38ϩ plasmablasts are highly concentrated on the lamina propria of the cervix and the vagina, which corroborates earlier observations of local populations of antibody producing cells in the human cervix. (25) Despite the predominance of plasmablasts in the cervix, which are highly enriched in specific Ig mRNA, (26) we observe an assortment of light and heavy chain V genes in the cervix. We can conclude that cervical IgA antibody is not restricted, and that diverse B-cell pool is found in the cervix.
CHAIN-SHUFFLING WITH CERVICAL V-GENES
We used guided selection to produce new MAbs to gp120 from cervical B cells libraries of HEPS prostitutes. The new gp120 specific VH and VL domains were combined to form completely Kenyan MAbs and these were tested for gp120 reactivity. Purified scFv fragments from MAb IgA6-30 lambda bound the recombinant gp120 JRFL in EIA much more strongly than the IgA6 VH-5 kappa, which also binds the clade B gp120 (Fig. 5) . The absence of competition of whole IgG B12 with cervical MAbs IgA6/5k and IgA6/30 lambda shows that a new epitope on gp120 is bound (Fig. 5b) . This is consistent with the unique reactivity of the IgA6/4L hybrid observed initially in flow cytometry (Fig. 2b) and suggests the IgA6 VH is specific to a different epitope on gp120, conserved on both the Clade A and B envelope protein oligomers. The epitope identified by IgA-6 VH may be immunodominant and/or protective on the cervix, however, its conservation among HIV-1 strains is not currently known.
The selection of new hybrid MAbs with altered epitope recognition is an expected feature of guided selection. (27) For example, light chain shuffling facilitates the selection of antibodies with a shift in epitope recognition. (23, 28) Herein we show that heavy chain shuffling and whole IgGb12 antibody competiton during the selection allows the recovery of heavy chains with novel gp120 epitope reactivity. Cervical antibody libraries from HEPS commercial sex workers are a useful source of lymphocytes for deriving human MAbs to STD pathogens.
The combinatorial antibody selection strategy works despite the scrambling of heavy and light chain pairs inherent to library construction. Guided-selection in combination with immune mRNA sources seems to work by generating a reasonable proportion of productive heavy-light chain combinations. (22) While it is possible that the representation of dominant antigp120 transcripts in vivo is simply too low for the usual library approach, there are several potential limitations to this study. For example, the number of HEPS individuals and whether there is a requirement for exposure of HEPS to have this specificity are both unknown. While our findings are compelling, especially in light of the in vivo resistance phenotype, we cannot rule out the possibility that the specificity may have been created by the chain-shuffling strategy. Chain shuffling is a constructive approach for obtaining binding clones as not all H/L combinations may be present in the original randomized library. (21) The advantages reside in the generation of large numbers of functional antibody combinations beginning with a single antibody template. (28, 29) For example, Kang et al. (29) showed that chain shuffling of hapten specific VH and VL pairs into an immune, but not a naive cDNA lambda phage library, produced new binding clones. Thus "immune" libraries are enriched in antigen-specific VH and VL partners compared with libraries from lymphocytes from unexposed mRNA sources. The small diversity in our libraries suggests it is unlikely that natural pairs of gp120 specific MAbs could be formed in vitro unless they are over-represented, for example, by plasmablasts, in the cervix.
The chain-shuffling strategy selected novel immunoglobulin binding domains to gp120. At the nucleotide level, clone IgA9 has greatest homology to a VH1-like gene (V1 ‫;30ء64‬ 91%) and clone IgA6 has highest identity to a VH3 related gene (V3 ‫;20ء66‬ 85%) (Fig. 3) . According to the NCBI databanks, clone IgA9 has a maximum identity of 85% at the inferred amino acid level with HV1B. IgA9 VH also has 74% identity a VH-domain from systemic B-cell cDNA selected from a phage Fab library on herpes simplex virus. (30) The IgA6 VH3 like gene has a maximum identify of 75% at the inferred amino acid level with previously identified V genes in the databank [HV3F (P01767)]. Planar-type binding sites, which are in general elicited against protein-antigens, tend to be formed by short CDR loops. (31) Analysis of the cDNA sequences of the selected cervical heavy chains IgA6 and IgA9 reveals relatively short but unique CDR3 regions of 9 inferred amino acid residues each. The selection of gp120-specific VH genes from the cervical B-cell pool of these Kenyan prostitutes supports the notion that V-genes with short CDR3 lengths may comprise high afinity antibodies elicited against commonly encountered antigens of the mucosal immune system. (32) The reduced length in the CDR3 region supports the binding of the cervical ScFv to different epitopes from the parental b12 molecule. The IgGb12 is proposed to utilize an extended H3 to access critical contacts of the CD4 binding site on gp120, (33) although b12 has not been crystallized while bound to any form of gp120.
The selection of new light chain partners for H31 VH from cervical B cells, while novel, is not surprising as light-chain promiscuity has been observed with gp120 specific VH domains. (34) Cervical light chains 5-kappa and 30-lambda have identity to previously published sequences of 85% and 74%, respectively. IGKV3 ‫10ء02‬ and has a IGKJ2‫10ء‬ joining region. The 30-lambda light chain has 74% identity with IGLV2-14‫30ء‬ and has a lambda IGLJ3‫20ء‬ joining region (Fig. 4) . Of note, the 30-lambda light chain is clearly polymorphic compared to the databank sequences. Codon 35 is deleted and an insertion in the CDR3 region, which could be due to true polymorphism or from somatic mutation during antigen-specific immune responses (35) or acquired during rearrangement and junctional diversification.
MAbs comprised of new VH and VL combinations are expected to target a different spectrum of HIV-1 antigenic variants for neutralization. For example, in vivo replacement of VL, termed receptor editing, (36) produces antibodies to the same epitope, as directed by the heavy chain, but utilize a different set of light chain contacts. (37) Indeed, designed insertions into the variable regions of MAbs can have variable effects upon anti-gen binding depending upon the type of antigen they are raised against. (38) While the cervical V genes we selected are somatically mutated and/or polymorphic, the role of polymorphic V genes in HIV-1 resistance remains to be determined. V genes encoding unselected human parotid IgA is also somatically mutated, (32) which likely reflects antigen-specific affinity maturation. Collectively, the relative importance of the heavy chain domain in determining antibody specificity (22) and the presence of somatically mutated gp120 specific IgA antibodies in the genital tract of HEPS individuals (8, 9) show that a localized gp120 specific B-cell response has occurred in Kenyan HEPS. Pools of potent MAbs to diverse HIV types will produce broad neutralizing coverage and help to delineate new epitopes for active vaccine discovery.
The molecular basis for immune exclusion of HIV-1 at the mucosal surface is not clear. Mucosal IgA has traditionally been attributed as being a major component of protection against STD pathogens despite limited molecular evidence. Limitations of our work include the indirect method of selection of these cervical MAbs to and the lack of available Kenyan gp120 to reflect the predominant clades of the HIV-1 virus at the outset of these experiments. The relevance of host co-receptors or even in vitro neutralization assays to sexual transmission is unclear. This is important as most HIV transmission is sexual and few broadly neutralizing gp120 MAbs have been derived from systemic B cells of HIV-positive individuals. There are several antibody-virus parameters that may differ in the cervix. First, for local protection, a high concentration of HIV-1-specific antibodies at the site of HIV-1 entry may be more important than high avidity in vivo. (39) Second, it is unclear if immunodominant B-cell epitopes targeted by systemic immune response are also immunodominant in immune responses, or to B cells on mucosal surfaces. Third, it is unclear if CD4-based cellular inhibition assays are relevant to the mode of entry of HIV-1 from mucosal surfaces. (40) Therefore, it is critical to adapt tools, like immune libraries, to be able to study the B-cell pools that first encounter HIV-1. Moreover, it will be important to test MAbs derived from the cervix on HIV-1 strains relevant to sexual exposures in that host. (41) In conclusion, we have successfully isolated and characterized the first functionally active anti-HIV 1 virus scFv MAbs from the human cervix. The cervix is a potentially valuable source of B-cell diversity for the generation of human MAbs to STD pathogens. The mucosal antibody pool should be well suited for in vitro modification strategies, like humanization, (42) for antibody against microbes as this pool is sensitized against a wide variety of pathogens. Clearly, these data lead the way for more studies aimed at the role of the cervical antibody repertoire in resistance to HIV, which appears to be broadly neutralizing. (43) Determination of the epitopes to which these antibodies were raised may lead to an effective vaccine for HIV-1 in humans. The use of antibody libraries to sample local mucosal B-cell responses of the urogenital tract has broad implications for STD vaccine research.
